Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine vs Morphine PCA for Mucositis Pain in Pediatric Cancer
NCT03825887Phase 3Completed
- Sponsor
- Children's Cancer Hospital Egypt 57357
- Start
- Feb 2018
- Primary completion
- Dec 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nalbuphine in oral mucositis (OM) (2 arms), sponsored by Children's Cancer Hospital Egypt 57357. Primary endpoints: Change in Pain Intensity (VAS) and Total Opioid Consumption at 7 days. Started Feb 2018; status: completed.
02
Drugs
nalbuphine
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT03825887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03825887.